CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-15 | Hessekiel Jeffrey Chief Legal & Admin Officer | Grant or award · Incentive Stock Option (Right to Buy) | +8,325 | 8,325 | ||
| 2026-03-15 | Hessekiel Jeffrey Chief Legal & Admin Officer | Grant or award · Non-Qualified Stock Option (Right to Buy) | +22,820 | 22,820 | ||
| 2026-03-15 | Lee Sung EVP, Chief Financial Officer | Grant or award | +20,646 | 92,062 | ||
| 2026-03-15 | Lee Sung EVP, Chief Financial Officer | Grant or award · Incentive Stock Option (Right to Buy) | +1,665 | 1,665 | ||
| 2026-03-15 | Lee Sung EVP, Chief Financial Officer | Grant or award · Non-Qualified Stock Option (Right to Buy) | +29,480 | 29,480 | ||
| 2026-03-15 | Malik Fady Ibraham EVP Research & Development | Grant or award | +27,306 | 165,935 | ||
| 2026-03-15 | Malik Fady Ibraham EVP Research & Development | Grant or award · Incentive Stock Option (Right to Buy) | +1,665 | 1,665 | ||
| 2026-03-15 | Malik Fady Ibraham EVP Research & Development | Grant or award · Non-Qualified Stock Option (Right to Buy) | +39,527 | 39,527 | ||
| 2026-03-09 | Callos Andrew EVP, Chief Commercial Officer | Sale | −2,582 | $60.72 | $157K | 47,858 |
| 2026-03-09 | Malik Fady Ibraham EVP Research & Development | Sale | −2,907 | $60.72 | $177K | 138,629 |
| 2026-03-09 | Blum Robert I President & CEO | Sale | −7,931 | $60.72 | $482K | 391,673 |
| 2026-03-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +11,000 | $39.13 | $430K | 76,440 |
| 2026-03-05 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −15,000 | $61.87 | $928K | 61,440 |
| 2026-03-05 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −11,000 | $61.88 | $681K | 50,440 |
| 2026-03-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +15,000 | $23.26 | $349K | 65,440 |
| 2026-03-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −11,000 | 24,403 | ||
| 2026-03-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −15,000 | 69,000 | ||
| 2026-03-02 | PARSHALL B LYNNE Director | Sale 10b5-1 | −5,000 | $61.21 | $306K | 17,933 |
| 2026-03-02 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +886 | $37.63 | $33K | 51,326 |
| 2026-03-02 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −886 | $61.62 | $55K | 50,440 |
Page 11 of 22 · 429 trades